BioSpace News Archive

Celltrion USA has signed a contract with Ventegra ®, a major U.S. Medical Benefits Manager (MBM) who administers pharmacy benefits through its Pharmacy Services Administration (PSA) model that has been effectively displacing traditional PBM’s.

Pfizer Inc. (NYSE: PFE) will present data across its infectious disease portfolio at the upcoming IDWeek 2023 held in Boston from October 11-15, 2023.

KDx Diagnostics Inc., a leading innovator in non-invasive bladder cancer tests, is pleased to announce the issuance of important patents in the US, EU, and South Korea relating to their joint work in developing new tests to aid in the treatment of bladder cancer.

GC Biopharma Corp. announced that GC1126A, its drug candidate for Thrombotic Thrombocytopenic Purpura, received an Orphan Drug Designation on September 27 from the U.S. Food and Drug Administration.

Spartan Medical Inc., a veteran-owned medical solutions company, is launching a campaign to raise awareness about the consequences of Surgical Site Infections and reduce SSIs in medical centers across the country.

Elligo Health Research®, the largest healthcare-enabling research organization, announced it is expanding its Study Marketplace platform with Syneos Health, a leading fully integrated biopharmaceutical solutions organization built to accelerate customer success.

Thermo Fisher Scientific, the world leader in serving science, today expanded its manufacturing capacity in St. Louis to support biologic therapies for diseases ranging from cancers to auto immune conditions to rare genetic disorders.

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH) today announced the speakers for its upcoming Investor & Analyst Event focused on the Developmental and Epileptic Encephalopathy (DEE) landscape and LP352, a first-in-class 5-HT2C receptor superagonist in development for the potential treatment of seizures associated with DEEs.

Miromatrix Medical Inc., a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients’ lives, announced that CEO Jeff Ross will present at the 2023 Cell & Gene Meeting on the Mesa in Carlsbad, CA.

The global breast cancer drugs market size is expected to be worth around US$ 40.4 billion by 2030, according to a new report by Vision Research Reports.